News | June 02, 2021
Progress on new ventures key for Aurobindo Pharma: ICICI Securities
Aurobindo has one of the most enduring generics ecosystems among peers
Aurobindo has one of the most enduring generics ecosystems among peers
The Department of Pharmaceuticals launched the PLI scheme for promoting domestic manufacturing of bulk drugs, with a financial outlay of Rs. 6,940 crore across 53 APIs over 6 years
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
PEL will explore the PLI scheme and apply if its beneficial.
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
